Cellectar Biosciences, Inc.
CLRBDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
15dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How CLRB's past catalysts played out
Paclitaxel
Non Small Cell Lung Cancer
NOV-002
Ovarian Cancer
NOV-205
Hepatitis C
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Paclitaxel | Phase 3 | Non Small Cell Lung Cancer | - | Patent 2034 |
NOV-002 | Phase 3 | Ovarian Cancer | - | - |
NOV-205 | Phase 2 | Hepatitis C | - | - |
Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Non Small Cell Lung Cancer
1 drug in this indication
Waldenstrom Macroglobulinemia
1 drug in this indication
Hepatitis C
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cellectar Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Cellectar Biosciences, Inc.'s (CLRB) pipeline across Phase 3, Phase 2. Its lead program is Paclitaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cellectar Biosciences, Inc.'s next FDA catalyst?→
Cellectar Biosciences, Inc.'s (CLRB) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLRB biotech catalysts?→
Add CLRB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cellectar Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.